Search research articles
Contact Us
Filters
Showing results (21-30 of 67) with videos related to
Page
of 7
Sort By:
The American Journal of Psychiatry
|
May 31, 2014
Decreased prefrontal cortical dopamine transmission in alcoholism
Rajesh Narendran, Neale Scott Mason, Jennifer Paris, et al.
Biological Psychiatry
|
March 11, 2023
Imaging Nociceptin Opioid Peptide Receptors in Alcohol Use Disorder With [<sup>11</sup>C]NOP-1A and Positron Emission Tomography: Findings From a Second Cohort
Savannah Tollefson, Clara Stoughton, Michael L Himes, et al.
Synapse (New York, N.Y.)
|
June 8, 2018
Failure to detect amphetamine-induced dopamine release in the cortex with [<sup>11</sup> C]FLB 457 positron emission tomography (PET): Methodological considerations
Joshua Gertler, Savannah Tollefson, Rehima Jordan, et al.
Biological Psychiatry
|
July 27, 2014
Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates
Rajesh Narendran, Hank P Jedema, Brian J Lopresti, et al.
Biological Psychiatry
|
April 8, 2019
Decreased Nociceptin Receptors Are Related to Resilience and Recovery in College Women Who Have Experienced Sexual Violence: Therapeutic Implications for Posttraumatic Stress Disorder
Rajesh Narendran, Savannah Tollefson, Kelli Fasenmyer, et al.
Synapse (New York, N.Y.)
|
September 22, 2018
Imaging phosphodiesterase-10a availability in cocaine use disorder with [<sup>11</sup> C]IMA107 and PET
Savannah Tollefson, Joshua Gertler, Michael L Himes, et al.
Neuropharmacology
|
June 20, 2024
Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
Nazzareno Cannella, Veronica Lunerti, Qianwei Shen, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
Veronica Lunerti, Qianwei Shen, Hongwu Li, et al.
The International Journal of Eating Disorders
|
May 5, 2011
Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa
Ursula F Bailer, Rajesh Narendran, W Gordon Frankle, et al.
Synapse (New York, N.Y.)
|
September 5, 2006
Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo
Rajesh Narendran, Mark Slifstein, Olivier Guillin, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 67) with videos related to
Sort By:
Page
of 7
The American Journal of Psychiatry
|
May 31, 2014
Decreased prefrontal cortical dopamine transmission in alcoholism
Rajesh Narendran, Neale Scott Mason, Jennifer Paris, et al.
Biological Psychiatry
|
March 11, 2023
Imaging Nociceptin Opioid Peptide Receptors in Alcohol Use Disorder With [<sup>11</sup>C]NOP-1A and Positron Emission Tomography: Findings From a Second Cohort
Savannah Tollefson, Clara Stoughton, Michael L Himes, et al.
Synapse (New York, N.Y.)
|
June 8, 2018
Failure to detect amphetamine-induced dopamine release in the cortex with [<sup>11</sup> C]FLB 457 positron emission tomography (PET): Methodological considerations
Joshua Gertler, Savannah Tollefson, Rehima Jordan, et al.
Biological Psychiatry
|
July 27, 2014
Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates
Rajesh Narendran, Hank P Jedema, Brian J Lopresti, et al.
Biological Psychiatry
|
April 8, 2019
Decreased Nociceptin Receptors Are Related to Resilience and Recovery in College Women Who Have Experienced Sexual Violence: Therapeutic Implications for Posttraumatic Stress Disorder
Rajesh Narendran, Savannah Tollefson, Kelli Fasenmyer, et al.
Synapse (New York, N.Y.)
|
September 22, 2018
Imaging phosphodiesterase-10a availability in cocaine use disorder with [<sup>11</sup> C]IMA107 and PET
Savannah Tollefson, Joshua Gertler, Michael L Himes, et al.
Neuropharmacology
|
June 20, 2024
Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
Nazzareno Cannella, Veronica Lunerti, Qianwei Shen, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
Veronica Lunerti, Qianwei Shen, Hongwu Li, et al.
The International Journal of Eating Disorders
|
May 5, 2011
Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa
Ursula F Bailer, Rajesh Narendran, W Gordon Frankle, et al.
Synapse (New York, N.Y.)
|
September 5, 2006
Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo
Rajesh Narendran, Mark Slifstein, Olivier Guillin, et al.
Page
of 7